Neeraj Agarwal, MD

Articles

Pinpointing Pivotal Prostate Cancer Data With Drs Agarwal and Shore

October 21st 2025

Neeraj Agarwal, MD, FASCO, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in prostate cancer presented during the 2025 ESMO Congress.

Key Takeaways on Updates in Bladder Cancer

April 1st 2024

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

Exciting New Approaches in Metastatic Urothelial Carcinoma

March 25th 2024

Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.

Treatment Sequencing Practices in Metastatic Urothelial Carcinoma

March 25th 2024

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

Later-Line Therapies for Metastatic Urothelial Carcinoma

March 18th 2024

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma

March 18th 2024

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

Clinical Insights on Recent Data in Metastatic Urothelial Carcinoma

March 11th 2024

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

Emerging Data in Metastatic Urothelial Carcinoma

March 11th 2024

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.

Dr Agarwal on QOL Considerations for Patients With Prostate Cancer

March 11th 2024

Neeraj Agarwal, FASCO, MD, discusses quality of life considerations for patients with prostate cancer.

Expert Insights on Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

March 4th 2024

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

March 4th 2024

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

Ongoing Research on Neoadjuvant Therapies in Muscle-Invasive Bladder Cancer

February 26th 2024

Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.

Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer (MIBC)

February 26th 2024

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.

Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

December 19th 2023

Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.

Triple Combination Therapies in RCC: Clinical Trial Insights

December 19th 2023

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

December 12th 2023

Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.

Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

December 12th 2023

Expert insight into how to discuss and manage treatment-related toxicities with cancer patients and their families, emphasizing the importance of early communication and vigilance.

Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

December 5th 2023

Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).

Sequencing and Second-Line Therapy in RCC: Patient Scenario

December 5th 2023

Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.

Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

November 28th 2023

Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.